

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number
WO 2004/049819 A2

(51) International Patent Classification⁷: **A23J 3/00**

KLOEK, William [NL/NL]; Distellaar 1, NL-5467 BR Veghel (NL).

(21) International Application Number:
PCT/EP2003/013678

(74) Agent: **VAN SOMEREN, Petronella, Francisca, Hendrika, Maria**; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).

(22) International Filing Date:
28 November 2003 (28.11.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02080019.9 29 November 2002 (29.11.2002) EP

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*): **CAMPINA B.V.** [NL/NL]; Hogeweg 9, NL-5301 LB Zaltbommel (NL).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **VEERMAN, Cecile** [NL/NL]; Troelstraweg 77, NL-6702 AG Wageningen (NL). **SAGIS, Leonard, Martin, Cornella** [NL/NL]; Gruttoweide 21, NL-6708 BC Wageningen (NL). **BAPTIST, Hendericus, Gerardus, Maria** [NL/NL]; Zuidelijke Parallelweg 229, NL-6812 BZ Arnhem (NL). **VAN DER LINDEN, Erik** [NL/NL]; Bovenbuurtweg 114, NL-6717 XC EDE (NL). **BOLDER, Suzanne, Godelieve** [NL/NL]; Leeghwaterstraat 32, NL-6717 CW EDE (NL).

(54) Title: METHOD FOR IMPROVING THE FUNCTIONAL PROPERTIES OF A GLOBULAR PROTEIN, PROTEIN THUS PREPARED, USE THEREOF AND PRODUCTS CONTAINING THE PROTEIN

(57) Abstract: The invention relates to a method for improving the functional properties of globular proteins, comprising the steps of providing a solution of one or more globular proteins, in which solution the protein(s) is/are at least partially aggregated in fibrils; and performing one or more of the following steps in random order: increasing the pH; increasing the salt concentration; concentrating the solution; and changing the solvent quality of the solution. Preferably, the solution of the one or more globular protein is provided by heating at a low pH or the addition of a denaturing agent. The invention also relates to the protein additive thus obtained, to the use thereof for food and non-food applications and to the food and non-food products containing the protein additive.

BEST AVAILABLE COPY

WO 2004/049819 A2

8/15

10/536713
JC06 Rec'd PCT/PTO 27 MAY 2005

WO 2004/049819

PCT/EP2003/013678

1

**METHOD FOR IMPROVING THE FUNCTIONAL PROPERTIES OF A
GLOBULAR PROTEIN, PROTEIN THUS PREPARED, USE THEREOF AND
PRODUCTS CONTAINING THE PROTEIN**

5 The invention relates to a method for improving the
functional properties of a globular protein. The invention
further relates to the protein thus prepared, to the use
thereof in various products as a protein additive, in
particular as a thickening agent, foaming agent, viscosity
10 enhancing agent and/or gelling agent and to the products
comprising such additive.

Food and non-food additives are inter alia concerned
with improving and maintaining product quality. They are for
example used to provide texture, consistency and stability.
15 For this they have functional properties such as foaming
properties, gelling properties, emulsifying properties,
thickening properties etc.

For food applications, additives can be roughly
divided into two groups, polysaccharides and proteins.
20 Examples of the first group having thickening properties are
e.g. guar gum, xanthan gum, locust bean gum. Examples of the
second group are e.g. milk proteins. Among the milk proteins,
whey proteins are widely used as ingredients in food products
for their ability to form gels.

25 β -Lactoglobulin is the major protein component of the
whey protein from milk. It is a globular protein with a molar
mass of 18.3 kDa and a diameter of about 2 nm. When the
protein is dissolved in an aqueous solution above a certain
critical concentration and heated above the denaturation
30 temperature (about 78°C) it forms a gel. The globular
structure unfolds at least partially and aggregates are
formed. The gel is formed by heat treatment if the

CONFIRMATION COPY

concentration of the protein is above a critical value (C_p), and an appropriate ionic strength is applied.

Polysaccharides have the advantage that they are effective thickeners in food products, even in low amounts.

5 However, the price of these hydrocolloids is normally high. Moreover, at elevated concentrations they may often give rise to taste defects. When used in dairy products like desserts, they are considered non-natural.

Proteins are normally less effective (on a w/w basis) 10 in thickening compared to hydrocolloids. Thus, even though their price may be considerably lower than for hydrocolloids, the higher dose required abolishes the price advantage.

As explained above, globular proteins form a gel when heated at neutral pH (around 7). However, the concentration 15 needed to form the gel is relatively high, e.g. more than 5% (w/w). Moreover, a gel thus obtained is irreversibly formed and is therefore not suitable for use as thickener in a range of products. The gel would have to be dried and/or comminuted thus losing its thickening capacity. On the other hand, if 20 whey proteins are thermally modified at neutral pH and low concentrations to avoid the undesired gel formation, the thickening capacity is very poor or not present at all.

In general there is a desire in the food industry to avoid additives that are non-natural. Proteins are a 25 potential natural source for the preparation of additives but their functional properties are often not comparable to the presently used additives.

There is thus a need for proteins that have good functional properties, in particular thickening, gelling, 30 foaming and emulsifying properties, and that are preferably highly effective at low concentrations.

In the research that led to the present invention it was found for β -lactoglobulin that the structures obtained at

low pH confer to the solution containing them a much higher viscosity and have thus a higher gelling capacity than the structures formed by heating β -lactoglobulin at pH 7. Gelling agents of such low pH are however not practically useful.

5 When a solution of β -lactoglobulin is heated at a pH of about 2, denaturation leads to a different type of aggregation than at neutral pH. This low-pH denaturation leads to protein aggregates which are joined by physical forces, whereas denaturation at a pH around 7 or higher will
10 lead to aggregates which are covalently bound through disulfide bonds.

 It was found that heating a solution of β -lactoglobulin at a pH around 2 leads to formation of fibrillar protein structures. As stated above, it is
15 generally accepted that these fibrils are constituted by aggregates held together by physical forces. The skilled person would expect that fibrils thus formed would decompose again upon pH increase.

 In the research that led to the present invention it
20 was surprisingly found that these fibrils are irreversibly formed when the heating time at or above denaturation temperature is longer than 10 minutes. The same observations were made for whey protein isolates and the teaching of the invention is thus applicable to globular proteins in general
25 and to β -lactoglobulin and whey protein isolates and concentrates in particular.

 It was furthermore found that similar fibrillar protein structures can be obtained when a denaturing agent is added to the solution comprising the globular protein.

30 The invention thus relates to a method comprising the steps of:

a) providing a solution of one or more globular proteins, in which solution the protein is at least partially aggregated in fibrils; and

b) performing one or more of the following steps in
5 random order:

- i) adjusting the pH of the solution to about neutral;
- ii) increasing the salt concentration in the solution;
- 10 ii) concentrating the solution;
- iii) changing the solvent quality of the solution.

In this way a protein additive is obtained having improved functional properties. Method step a) provides the
15 fibrillar structures in the protein solution whereas method step b) triggers the protein such that it is ready to perform its function as a foaming, thickening, gelling or emulsifying agent upon addition thereof to the final product.

Providing a solution of the one or more globular
20 proteins, in which solution the one or more proteins are at least partially aggregated in fibrils, can be achieved in various ways. In a first embodiment the fibril-containing solution of the one or more globular proteins is provided by heating a solution of the protein above room temperature,
25 preferably at a temperature between 50 and 100°C, at a pH between 0.5 and 4, preferably between 0.5 and 3. In an alternative embodiment the fibril-containing solution of the one or more globular proteins is provided by adding a denaturing agent to the solution.

30 The denaturing agent can be a hydrotropic or chaotropic agent and is for example selected from the group consisting of ureum, guanidinium chloride, alcohols, such as methanol, ethanol, propanol, butanol, trifluorethanol. The

treatment with the denaturing agent can be performed at a pH between 0.5 and 14, preferably between 3 and 11, more preferably between 5 and 9.

In solutions containing globular proteins that are
5 treated in this way, fibrils are formed having an unexpectedly high gelling and/or thickening and/or foaming and/or emulsifying capacity. The fibrils are irreversibly formed and can be used at any desired pH or ionic strength.

Heating the solution in the first embodiment of step
10 a) is preferably performed during at least 10 minutes, preferably at least 1 hour, more preferably at least 6 hours, most preferably at least 8 hours.

The pH of the treatment of the first embodiment of step a) is preferably below 2.8, preferably below 2.5, more
15 preferably below 2.2. Suitable acids for adjusting the pH to this value are food grade acids, such as hydrochloric acid, phosphoric acid, nitric acid or sulphuric acid.

The total heating time required to obtain the effect may be achieved by batch wise heating, continuous flow
20 heating or a combination of subsequent heating steps, e.g. by means of circulating a solution through a heating system.

Optionally, the solution is cooled before performing one or more of steps i) to iii).

It is preferred to cool the solution to a temperature
25 between the denaturation temperature and 20°C, preferably between the denaturation temperature and 5°C.

When the pH is increased this is preferably to a value between 3.9 and 9, preferably to about neutral pH. Most food applications have a neutral, near neutral or slightly
30 acidic pH.

Advantageously, the salt concentration is increased to a maximum of 0.2 M, preferably to 0.1 M. The salt used for increasing the salt concentration is preferably the salt of a

divalent ion, preferably calcium. It was found that by adding calcium the functional properties are further improved.

According to a preferred embodiment step i) is performed prior to step ii) because pH adjustment in dilute
5 systems is easier to carry out.

Changing the solvent quality of the solution can be performed by removing the denaturing agent, for example by dilution or dialysis.

In a further embodiment of the invention the method
10 further comprises addition of already formed fibrils to the solution of globular proteins prior to the heating step. It was found that by means of this so-called seeding the heating time could be reduced. It was furthermore found that an even lower critical gelling concentration (Cp) could be obtained
15 in samples that had been seeded as compared to samples that were not seeded. Seeds for addition to the solution can be prepared in the same way as the protein of the invention.

In order to obtain a dry product which is more stable upon storage the method further comprises the step of drying
20 the solution to obtain a dry product. It was found that upon reconstituting the protein additive of the invention from the powder obtained after drying the same or similar functional properties were obtained. It is practical when the drying comprises spray drying. The dry product is preferably a
25 powder. Alternatively granulates can be envisaged.

Furthermore it is possible to dilute a gel obtained after concentrating the heated solution according to step b) iii) of the method to a less viscous product by addition of a pH 2 solution. The same applies to a solution treated
30 according to step b) ii) by lowering the salt concentration again.

Advantageously, the globular protein is a protein that is substantially non-denatured and is capable of being

thermally denatured at a temperature at or above the denaturation temperature of the protein or chemically denatured.

The method of the present invention can be performed
5 with a wide variety of globular proteins, such as whey proteins, egg albumins, blood globulins, soy proteins, wheat proteins, in particular prolamines, potato proteins or pea proteins. In a preferred embodiment, the globular protein is a whey protein isolate or a whey protein concentrate,
10 preferably a whey protein concentrate enriched in (e.g. > 40%) β -lactoglobulin. In a much preferred embodiment the globular protein is β -lactoglobulin.

In a further embodiment the globular protein is the whey protein isolate powder (95% protein, w/w) that is
15 commercially available under the name Bipro™ and is composed of ~70% β -lactoglobulin, ~18% α -lactalbumin, ~6% bovine serum albumin, and ~6% immunoglobulins. The functional properties of this product after having been subjected to the method of the invention can be further improved by purifying
20 the product prior to heating at low pH. Such purification comprises acidification to pH 4.75, centrifugation and use of the supernatant. This treatment results in loss of about 10% (aggregated) protein, mainly BSA.

The invention further relates to a protein additive
25 for food and non-food applications based on a system of one or more proteins that are aggregated to form fibrils, characterized in that the protein additive has improved functional properties as compared to a similar protein additive based on a system of the same one or more proteins
30 in the same concentration in which the proteins are not aggregated into fibrils. Fibrils in this respect are preferably fibrils consisting of protein and having an aspect ratio of 5 or higher. The aspect ratio is the ratio between

length and width or length and height or length and diameter. The length of the fibrils is preferably equal to or above 100Å and equal to or below 1 mm, preferably below 100 µm. These fibrils can be made visible by means of a microscope.

5 The above described protein additive can be obtained by the method of the invention or by any other means that leads to the above described structural properties.

 The protein additive of the invention can be used as a stabilizer of foams, dispersions and emulsions. Foams are
10 systems of a gas in a liquid. Emulsions are liquids in liquids and dispersions are solids in liquids. Usually these systems cannot exist without the help of a stabilising agent that helps in maintaining the disperse phase uniformly distributed in the continuous phase. The protein additive of
15 the invention was found to be very suitable for this purpose.

 The protein additive can be used in food stuffs, such as dairy products, for example (aerated) desserts, yogurts, flans, in bakery or confectionary applications, such as frappe, meringue, marshmallows, in cream liqueurs or in
20 beverage foamers, such as cappuccino foamers. When using β-lactoglobulin, whey protein concentrate or whey protein isolate as the globular protein that constitutes the protein additive the product obtained can be an all milk product.

 Whey protein concentrates normally comprise 25-90%
25 (w/w) whey protein. Whey protein isolates usually comprise > 90% whey protein.

 The protein additive of the invention can also be used in meat products, e.g. comminuted meat products (Frankfurter sausages), hamburgers, luncheon meat, pâte's,
30 poultry, fish meat products or meat replacers on vegetable basis, to enhance the water-binding and/or texture of the product.

Alternative applications of the protein additive of the invention can be found in non-food products such as paints, cosmetics, toothpastes, deodorants etc.

The invention further relates to products comprising
5 the protein additive of the invention, such as food stuffs, in particular dairy products or meat products, but also non-food products, e.g. paints, cosmetics, toothpastes, deodorants.

According to a further aspect thereof the invention
10 relates to a protein composition comprising one or more particles having texturizing properties, wherein the protein molecules are aggregated into fibrils. Texturizing properties comprise the ability to promote or modify the viscosity or gelling ability of a product containing the composition.
15 Preferably, the fibrils have an aspect ratio, which is defined as the ratio between length and width or length and height or length and diameter, of 5 or higher. The length of the fibrils is preferably equal to or above 100Å and equal to or below 1 mm, preferably below 100 µm.

20 The protein additive of the invention has improved functional properties. Functional properties comprise thickening capacity, gelling capacity, foaming capacity and emulsifying capacity and all have to do with the structure and texture of the product containing the additive. The fact
25 that the functional properties of the additive are improved means that the capacity to induce gelling, foaming, thickening or emulsification in the product containing the protein additive is improved as compared to the capacity to do so of the same protein in the same concentration but which
30 is not subjected to the method of the invention.

The present invention will be further illustrated in the examples that follow and that are not intended to limit

the invention. In the Examples reference is made to the following figures.

Figure 1A shows a TEM photograph of Bipro™ treated according to the invention after different heating times.

5 **Figure 1B** shows TEM photographs of β -lactoglobulin treated according to the invention after neutralization to different pHs.

Figure 2A shows meringue foam of treated and untreated Bipro™ prior to drying.

10 **Figure 2B** shows meringue foam of treated and untreated Bipro™ after drying.

Figure 3 shows cappuccino foam prepared with treated and untreated Bipro™.

15 **Figure 4** shows the overrun of a foam prepared with treated and untreated Bipro™.

Figure 5 shows the foam stability in time of a product prepared with treated and untreated Bipro™.

Figure 6 shows the drainage in time of a foam prepared with treated and untreated Bipro™.

20 **Figure 7** shows the drainage in time of a foam prepared with treated and untreated Bipro™.

EXAMPLES

EXAMPLE 1

25 Preparation of β -lactoglobulin gels according to the invention, and determination of critical gelling concentration

30 β -Lactoglobulin (β -lg) was obtained from Sigma (L-0130) and is a mixture of the genetic variants A and B. The protein was dissolved (3% w/w) in a HCl solution at pH 2. To remove traces of calcium ions from the β -lg, and to obtain a protein solution with the same pH and ionic strength as the solvent, the protein was diluted repeatedly with HCl solvent

and filtered through a 3K filter in an Omegacell™ membrane cell (Filtron) at 4°C and a maximum pressure of 3 bar. The procedure was stopped, when the pH and conductivity of the diluted solution and the solvent were the same.

5 The β -lg solution was centrifuged at 22600g for 30 min. To remove any traces of undissolved protein, the supernatant was filtered through a protein filter (FP 030/2, 0.45 mm, Schleicher & Schuell). A UV spectrophotometer was used to determine the β -lg concentration at a wavelength of
10 278 nm.

β -Lactoglobulin (w/w) as prepared above diluted to a concentration of 2% was heated at 80°C for 10 h in a water bath. After cooling, the pH was adjusted to pH 7 or 8 with 0.1 and 1 M NaOH. Various CaCl_2 concentrations (0.005,
15 0.0075, 0.01, 0.05, and 0.1 M) were added very carefully on ice, and the solution was mixed well. After this procedure, the solution was poured into the VOR rheometer (Bohlin concentric cylinder geometry C14) to determine the critical gelling concentration. The sample in the VOR was heated from
20 3°C to 25°C. After 3 h in rest, a strain sweep was performed (frequency 1 Hz, temperature 25°C, strain 0.000206-0.206).

The procedure was repeated for various protein concentrations. To determine the critical gelling concentration C_p , first the G' (the "elastic modulus", a
25 characteristic for the elastic component of a system) was determined for various protein concentrations (in the linear region of the curve). A plot was made of $(G')^{1/t}$ versus concentration c , for t ranging between 1.7 and 4.5. t is a scaling factor. In the fitting procedure, we make use of the
30 physical fact that extrapolation of $(G')^{1/t}$ to zero should yield the same C_p for all $t > 0$. The scaling assumption has the implication that when t is close to the correct value, the data points will be on a straight line. When t is larger than

the correct value, the fit through the points will bend away from the straight line and will lie below it. When t is smaller than the correct value, the fit through the points will also bend away from the straight line but will now lie
5 above it. In that case, the slope of the fit at the intercept with the horizontal axis will be zero. Therefore, in the fitting procedure we use the fact that the curvature of the fit will change if different values for t are chosen, while the intercept C_p will have to remain the same.

10 C_p was determined from fits through the data points that are closest to a straight line in determining an average intercept, C_p . It appeared that the C_p values for the protein system according to the invention were considerably lower than for the reference (not-modified) protein system.
15 (see examples)

The results of this experiment are shown in **Table 1**.

EXAMPLE 2

Preparation of β -lg gels according to the conventional
20 (neutral pH) gelation method, and determination of the
critical gelling concentration

β -Lactoglobulin (β -lg) was obtained from Sigma (L-0130) and is a mixture of the genetic variants A and B. The protein was dissolved (3% w/w) in a HCl solution at pH 2. To
25 remove traces of calcium ions from the β -lg, and to obtain a protein solution with the same pH and ionic strength as the solvent, the protein was diluted repeatedly with HCl solvent and filtered through a 3K filter in an Omegacell™ membrane cell (Filtron) at 4°C and a maximum pressure of 3 bar. The
30 procedure was stopped, when the pH and conductivity of the diluted solution and the solvent were the same.

The β -lg solution was centrifuged at 22600g for 30 min. To remove any traces of undissolved protein, the

supernatant was filtered through a protein filter (FP 030/2, 0.45 mm, Schleicher & Schuell). A UV spectrophotometer was used to determine the β -lg concentration at a wavelength of 278 nm.

5 3% β -lg samples at pH 7 or 8 were heated at 80°C for 30 min. After cooling, 0.01 M CaCl_2 was added very carefully on ice, and the solution was mixed well. After this procedure, the solution was poured in the VOR (Bohlin concentric cylinder geometry C14). The sample in the VOR was
10 heated from 3°C to 25°C. After 3 h in rest, a strain sweep was performed (frequency 1 Hz, temperature 25°C, strain 0.000206-0.206). Subsequently the critical gelling concentration of the conventionally formed β -lactoglobulin gel was measured. The results are shown in Table 1.

15

Table 1

Determination of the Critical gelling concentration
(gels prepared according to examples 1 and 2)

Heating conditions	Example no.:	Final pH	[mM] CaCl_2	Critical gelling concentration (% w/w)
pH 2, 10 hrs, 80°C	1	7.0	0	1.3
pH 2, 10 hrs, 80°C	1	7.0	5	1.1
pH 2, 10 hrs, 80°C	1	7.0	7.5	1.0
pH 2, 10 hrs, 80°C	1	7.0	10	0.1
pH 2, 10 hrs, 80°C	1	7.0	50	0.6
pH 2, 10 hrs, 80°C	1	7.0	100	0.7
pH 2, 10 hrs, 80°C	1	8.0	10	0.4
pH 2, 10 hrs, 80°C	1	8.0	50	0.6
pH 2, 10 hrs, 80°C	1	8.0	100	0.9
pH 7, 0.5 hrs, 80°C	2	7.0	10	No gel formed at 3%
pH 7, 0.5 hrs, 80°C	2	8.0	10	No gel formed at 3%

The results show that β -lactoglobulin modified by the acid pretreatment has a higher gelling ability than β -lactoglobulin which is not acid-modified.

EXAMPLE 3**Modification of Bipro™**

Bipro™, a whey protein isolate powder (95% protein, w/w), was obtained from Davisco, USA. Besides β -

5 lactoglobulin, Bipro™ also contains α -lactalbumin, bovine serum albumin and immunoglobulines.

Modification of Bipro™ was carried out as follows:
Four Bipro™ solutions were prepared in demineralised water in concentrations of 3, 4, 5 and 6% w/w. The pH was adjusted to
10 pH 2, using HCl. The solutions were heated for 10 hours at 80°C. After cooling, the samples were neutralised with NaOH to pH 7, and cooled further to 3°C, after which CaCl₂ (5 mM) was added to half of the samples. After 3 hours, all samples were assessed visually. The results are given in table 2.

15 A control experiment was carried out in the following way. Bipro™ solutions in demineralised water were made (3, 4, 5, 6% w/w) having a pH of 7. The solutions were heated at 80°C for 10 hrs, then cooled to 3°C and CaCl₂ was added to half of the samples. After 3 hours, the samples were assessed
20 visually. The results are shown in Table 2.

Table 2

Visual rheological properties of modified and not-modified Bipro™ (from Example 3)

25

Bipro™ samples:	no CaCl ₂ added	5 mM CaCl ₂ added
pH 2 modified and neutralised: (% w/w)		
30 3	Viscous solution	Gel
4	Very viscous sol.	Gel
5	Very viscous sol.	Firm gel
6	Very viscous sol.	Very firm gel

	Not modified:		
3		Low viscous liquid	Liquid
4		Low viscous liquid	Liquid
5		Low viscous liquid	Liquid
6		Low viscous liquid	Liquid

From the table it clearly follows that treatment according to the invention, of a whey protein product comprising different types of protein, also leads to strongly enhanced gelling capacity and a strong increase in viscosity.

EXAMPLE 4

Effect of seeding

15 *Introduction*

The objective of this example was to study the effect of addition of seeds to fresh protein material prior to heating at pH 2. The total protein concentrations, the ratios between fresh protein material and seeds (fresh/seeds), and the heating time of both seeds and the mixtures of fresh and seeds were varied. The total protein concentration at which seeds were made was kept constant, in order to have the same seeds in the different experiments. The protein material was Bipro™, a whey protein isolate powder (95% protein, w/w).

25

Materials and methods

Bipro™ was obtained from Davisco, and is composed of ~70% β -lactoglobuling, ~18% α -lactalbumin, ~6% bovine serum albumin, and ~6% immunoglobulins. The protein powder was dissolved in NANOpure™ water and left to stir at room temperature for 3 hours. Next the pH was adjusted to pH 4.75, using 6 M HCl. The protein solution was centrifuged at 12000 rpm for 30 min at room temperature, using a SLA-1500 super lite aluminium rotor in the Sorvall RC-5B refrigerated superspeed centrifuge. At pH 4.75, which is close to the iso-

electric point, undissolved protein is precipitated. HPLC analysis shows that about 50% of the BSA present in Bipro™ is being removed in this centrifugation step, indicating that the BSA was aggregated. To remove any traces of undissolved protein that did not end up in the pellet the supernatant was filtered through a protein filter (FD 30/0.45 mm Ca-S from Schleicher & Schuell). The centrifugation step at pH 4.75 is further referred to as "purification", meaning removal of aggregated and undissolved material, and the material is called "purified Bipro™".

After centrifugation and filtration the pH of the Bipro™ solution was set at pH 2, using 6 M HCl. The protein concentration was determined using a UV spectrophotometer and a calibration curve of known protein concentrations at wavelength 278 nm.

A Bipro™ stock solution of 1.2 % (w/w) at pH 2 was prepared according to the method described above. Different samples were taken and heated for 2, 5, or 10 h at 80°C. After heating the samples were cooled and stored in a refrigerator. Part of each sample was diluted to 0.8 and 0.4% Bipro™. Also the unheated Bipro™ solution was diluted to 0.8 and 0.4% Bipro™. These "stock" solutions of unheated (fresh) and heated material (seeds) after different heating times were mixed in different ratios and heated for different times at pH 2 and 80°C.

Cold gelation experiments with seeds made at 1.2% Bipro™ were performed as follows. Seeds that were made by heating Bipro™ from the 1.2% stock solution were used after dilution with NANOpure™ adjusted to pH 2 with 6M HCl to the required total concentrations. The total Bipro™ concentrations studied for this batch were 0.4%, 0.8%, 1.0%, and 1.2% Bipro™. Unheated and heated material were mixed in different ratios (0% seeds, 10% seeds, 20% seeds, 70% seeds,

and 90% seeds) and these mixtures were heated for 10 h, at pH 2 and 80°C. After heating, the samples were cooled and set at pH 7, using 1.0 M and 0.1 M NaOH.

Another set of cold gelation experiments was done, but
5 this time the seeds used were prepared at a Bipro™
concentration of 2.0%. In order to be able to go to higher
total protein concentrations when mixing seeds and fresh, and
also using the same seeds for those different total protein
concentrations, a higher concentration for preparing the seeds
10 was needed. The total Bipro™ concentrations studied for this
set were 0.8%, 1.0%, 1.2%, 1.4%, and 1.6% Bipro™. Also here
fresh and seeds were mixed in different ratios and heated for
10 h. at pH 2 and 80°C. After heating, the samples were cooled
and set at pH 7, using 1.0 M and 0.1 M NaOH.

15 In order to see the effect of addition of seeds of
non-dialysed, purified Bipro™, a series of test tubes was
filled. The mixtures (at pH 2) were heated for either 2, 5, or
10 hours at 80 °C. After cooling the samples to room
temperature and overnight storage the tubes were visually
20 examined. All gelation experiments were performed at 10 mM
CaCl₂.

The samples that were heated in the presence of seeds
and subsequently cooled and set at pH 7 were cooled on ice
prior to addition of CaCl₂, in order to slow down the reaction
25 rate of cold gel formation upon addition of calcium. A Paar
Physica MCR 300 stress controlled rheometer with a concentric
cylinder geometry (CC10) was used. The rheometer was cooled to
3°C before the sample was put into the geometry. The rheometer
was heated to 25°C. After 3 h of rest at 25°C a strain sweep
30 was performed (frequency 1 Hz, temperature 25°C, strain 0.001-
1).

Results

Mixtures of seeds and fresh Bipro™ of different concentrations (%) (w/w) were heated for 2, 5, or 10 h at pH 2 at 80°C. After cooling of the samples they were visually examined. It was found that upon the addition of seeds, gelation occurs at a lower total protein concentrations than when no seeds are present. Furthermore it was found that for a higher total protein concentration a higher G' is observed. When a higher amount of seeds is present during heating, a higher G' is observed and when the added seeds were heated for a longer time, the resulting G' after mixing with fresh and heating again is higher than for shorter heating time of the seeds. In addition, longer heating of the mixtures of fresh and seeds result in higher G' .

When plotting the graphs for different total Bipro™ concentrations for a certain amount of seeds present upon heating, C_p values per seeds-concentration were determined. From the linear regime of the strain sweep curves (i.e. where the G' is independent of the strain), G' was determined. The method to determine C_p and t is described by Van der Linden and Sagis, *Langmuir* 17, 5821 (2001), which is the same method as in Example 1.

The resulting C_p and t values for the different amount of seeds present during heating of the samples are given in Table 3.

Table 3

Calculated values for C_p and t

Amount of seeds	C_p	t
0%	$0.58\% \pm 0.12$	1.91 ± 0.33
10%	$0.53\% \pm 0.03$	1.84 ± 0.12

19

20%	$0.20\% \pm 0.12$	1.84 ± 0.30
70%	$0.18\% \pm 0.10$	1.81 ± 0.20
90%	$0.57\% \pm 0.10$	2.17 ± 0.35

5 From **Table 3** it can be concluded that the critical percolation concentration (also known as critical gelling concentration) is decreased due to the presence of seeds. This means that less protein is needed for obtaining the same result.

10 **EXAMPLE 5**

Transmission Electron Microscopy

Bipro™

TEM micrographs were made in order to obtain insight in the structures formed upon heating the Bipro™ samples for
15 different heating times and to see whether there are differences between samples. The samples (heated at 1.2% Bipro™ at pH 2) were diluted to 0.05%. The TEM samples were prepared by negative staining. A drop of the diluted solution was deposited onto a carbon support film on a copper grid. The
20 excess was removed after 15 s using a piece of filter paper. A droplet of 2% PTA (pH 5.5) was added for 15 s, any excess being removed with filter paper. The grid was left to dry to the air. Electron micrographs were made using a Philips CM 12 Transmission Electron Microscope operating at 80 kV. The
25 sample that was heated for 2 h did not show fibrils. In the samples that were heated for either 5 or 10 h long fibrils were visible (see **Figure 1A**).

β-lactoglobulin

30 Transmission Electron Microscope (TEM) photographs were made of the samples after heat treatment at pH 2, and of

samples that were neutralized at pH 7 and 8 (see **Figure 1B**). From this it follows that the fibrils do not disintegrate upon neutralisation.

5 Description of the sample preparation for TEM:

The following samples:

a) 2 % beta-lactoglobuline, pH 2, 10 hrs 80°C

b) as a), but neutralized to pH 7 using 1.0 and 0.1 M NaOH

c) as a), but neutralized to pH 8 using 1.0 and 0.1 M NaOH

10 were diluted to 0.04 % beta-lactoglobuline. The TEM samples were prepared by negative staining. A drop of the diluted solution was deposited onto a carbon support film on a copper grid. The excess was removed after 30 seconds using a piece of filter paper. A droplet of 2 % uranyl acetate pH 3.8, was
15 added for 15 seconds; any excess was removed again as before. Electron micrographs were made using a Philips CM 12 Transmission Electron Microscope operating at 80 kV.

EXAMPLE 6

20 Effect of pH, drying and concentration on overrun and stability of foam

Introduction

Various experiments have been performed in which foam properties of the fibrils formed are determined. In this
25 the effect of pH, drying and concentration at which the fibrils are formed on the foam properties is tested.

Material and Methods

A Bipro™ solution is prepared and purified as
30 follows. Bipro™ is solubilised in water in a concentration of 10, 12.5 en 15%. These solutions are acidified to pH 4.75 with 6M HCl by adding the HCl solution drop by drop under constant stirring. At pH 4.75 the Bipro™ solution turns white with

large flakes which sediment slowly. The solution is centrifuged at 10 min, 9000 rpm in a Sorvall superspeed RC2-B centrifuge, GSA rotor (13.200g). The clear supernatant is collected and spray dried at pH 4.75. The pellet is discarded.

5 The fibrils are formed by heating the purified Bipro™ solution at pH 2 (acidified with 6M HCl) during 10 hours. The solution is cooled down by gradually (0.5-1 hour) cooling the water bath from 80 to 20°C. The pH is increased by adding NaOH (2M) under stirring. The solution turns white
10 between pH 4 and 5.5 and slowly becomes clear upon further increasing the pH.

Fibrils formed of purified Bipro™ are called 2-step fibrils and in case non-purified Bipro™ is used it is called 1-step fibrils.

15 Foam is obtained by whipping under standard conditions a 3% protein solution for 5 min at speed 3 in a Hobart mixer (model N-50) provided with a standard bowl and wire whisk. The foam is transferred to a round bottom bowl of stainless steel with a diameter of 10 cm, height 5.4 cm, a
20 volume of 270 ml and a weight of 52.1 g.

The overrun and stability are measured as follows. For the overrun the round bottom bowl is weighed (A) and filled with foam. A spatula is used to straighten the surface and this bowl is weighed again (B). For the stability the foam
25 is brought in a weighted powder funnel (D) and the filled funnel (C0) is weighed. The funnel is brought above the cylinder and the cylinder (Wt) and funnel (Et) are weighed after 15, 30, 45 and 60 min.

The overrun and stability (drainage) are calculated
30 as follows.

$$\text{Overrun (\%)} = (V * S / (B - A) * 100) - 100$$

V = volume round bottom bowl

S = specific weight protein solution-

B = weight bowl and foam

A = weight bowl

5

$$\text{Stability (\%)} = (((C - D) - (C - E)) / (C - D)) * 100$$

C = funnel + foam after filling

D = weight empty funnel

10 Et = weight funnel after 15, 30 45 or 60 min drainage.

$$\text{Drainage (\%)} = Wt / (C - D) * 100$$

Wt = weight cylinder after 15, 30, 45 or 60 min drainage

15 C = weight funnel and foam after filling

D = weight empty funnel.

Results and Discussion

Effect of pH

20 In Table 4 the results of the foam tests of native Bipro™ and 2-step fibrils are shown. The results show that whipping at pH 7 gives a high overrun and a 76% drainage in 60 min. Whipping of the same fibrils at pH 5 gives 50% lower overrun but only 32% drainage in 60 min. As a comparison
25 purified Bipro™ is whipped and this gives a low overrun and a high drainage.

Table 4

30

code	modification		whipping test		overrun	drainage	drainage	drainage	drainage
	% Bipro	pH	% Bipro	pH	%	% (15 min)	% (30 min)	% (45 min)	% (60 min)
pH 7 fibrils	4	2	3	7	3599	2	35	61	76

5	pH 6 fibrils	4	2	3	6	2713	0	9	33	54
	pH 5 fibrils	4	2	3	5	1737	0	6	20	32
	pH 7 native	4	2	3	7	1676	29	70	84	90
	pH 6 native	4	2	3	6	1306	20	60	74	81
	pH 7 native	4	2	3	5	1525	8	46	64	73

Effect of concentration at which the fibrils are formed

2-step Bipro™ fibrils are formed at 3-6% Bipro™
 15 concentration. These solutions are diluted to 3% and whipped.
 The concentration at which the fibrils are made does hardly
 effect the overrun, the drainage seems somewhat smaller in
 case the fibrils are made at higher concentrations (**Table 5**).

20 **Table 5**

code	modification		whipping test		overrun	drainage	drainage	drainage	drainage
	% Bipro	pH	% Bipro	pH	%	% (15 min)	% (30 min)	% (45 min)	% (60 min)
3% fibrils	3	2	3	7	3665	0	17	43	55
25 4% fibrils	4	2	3	6	3773	0	13	34	53
5% fibrils	5	2	3	5	3829	0	5	26	43
30 6% fibrils	6	2	3	7	3467	0	1	18	40

Effect of drying

The whipping experiments are performed with 1-step fibrils. Additionally, there is salt added before heat treatment and salt is also present during whipping. In general addition of salt causes the formation of larger structures during heating and a better overrun and foam stability.

The results in **Table 6** show that freeze drying hardly effects the overrun and the draiage. It also shows the poor foam properties of native Bipro™.

10

Table 6

code	modification			whipping test			overrun	drainage	drainage	drainage	drainage
	% Bipro	pH	NaCl mM	% Bipro	pH	NaCl mM	%	% (15 min)	% (30 min)	% (45 min)	% (60 min)
freeze dried fibril powder	4	2	30	3	7	22.5	2159	0	20	39	57
fresh fibrils (prior to freeze drying)	4	2	30	3	6	22.5	2278	0	16	43	59
native Bipro™	4	2	30	3	5	30	464	74	86	91	92

15

20

EXAMPLE 7Foaming test

75 Grams of a 3% solution of purified Bipro™ and purified Bipro™ treated according to the invention were whipped in a Hobart N 50 mixer for 5 min at speed 3. The overrun of Bipro™ was 1600%, whereas the overrun of Bipro™ fibrils (i.e. Bipro™ treated according to the invention) was 3400%. When non-purified Bipro™ without fibrils was used as a starting product the overrun was only 450%. **Figures 4-7** show the results. It follows that Bipro™ fibrils show a very high

25

30

overrun. The foam drains in time, but drainage is much quicker for untreated Bipro™.

EXAMPLE 8

5 Use of the protein additive of the invention as a thickening agent in custard-like cream dessert

Modified Bipro™ was obtained by freeze-drying a sufficient amount of the neutralized 5% solution as described in Example 3. The powder thus obtained can be used directly in
10 the applications below, or mixed with calcium chloride prior to use in the applications.

Composition:

	A. traditional	B. invention
15	(grams)	(grams)
Skim milk	355	355
Cream (40% fat)	65	65
Water	444	444
20 Protein:		
Esprion 300U	10	-
(DMV International)		
Modified Bipro™	-	0.8
Saccharose	60	60
25 Lactose	28	37
Modified starch	38	38
(C*tex 06201 from Cerestar)		
Carrageenan	0.3	0.3
(CL 360C, Danisco)		
30 Flavouring	q.s.	q.s.
(e.g. vanilla)		
Colouring	q.s.	q.s.

Esprion™ 300U is a whey protein concentrate having 30% protein (w/w).

All the ingredients were mixed in the cold milk (approx. 7°C), and left to hydrate for 20 minutes at a temperature < 10°C. The mixture was heated for 10-20 seconds at 140°C using an UHT pasteuriser (APV, Denmark) fitted with a holding tube, and subsequently cooled to < 10°C, and packaged. Storage was at a temperature below 10°C.

Products obtained are tested by a panel, and a texture measurement was carried out using the Stevens Texture Analyser™ (Stevens Instruments, UK) equipped with a disc probe. The resistance of the probe was measured as the probe penetrates the sample within a determined period of time over a specified distance.

The test results showed that, despite the low dosage of modified Bipro™, the texture of Sample B was much better (better mouth feel, higher viscosity) than sample A.

EXAMPLE 9

Use of the protein additive of the invention as a thickening agent in in drinking yogurt

Yogurt A (reference) was prepared as follows. 117 grams of Esprion™ 300U was dissolved in 1 liter of water. 280 Grams of this solution was mixed with 720 grams of skim milk. The final protein concentration of this solution was 3.5% (w/w). The solution was heated to 65°C and homogenised at this temperature, after which it was pasteurised for 6 minutes at 92°C. The pasteurised milk was cooled to 32°C, and inoculated with a yogurt culture (0.02 % Yoflex™ 380 from Chr. Hansen). Fermentation was continued for approx. 14-16 hours until a pH of 4.2-4.3 was reached.

Drinking yogurt was prepared by blending the freshly prepared yogurt with a fruit preparation (25% water,

25% fruit juice, 50% sugar obtainable from Wild, Germany) in a ratio 80% yogurt/20% fruit preparation. Before adding to the yogurt, the fruit preparation was pasteurised at 85°C for 5 minutes and cooled to 20°C.

5 The mixture of yogurt and fruit preparation was subjected to a low-pressure homogenisation at 1-3 MPa. The drinking yogurt was then cooled to < 10°C , packaged and stored below 10°C.

 Yogurt B including the protein preparation
10 according to the invention was prepared in a similar way as A but the starting milk was composed of 280 grams of an 0.8% (w/w) solution of modified Bipro™ (from the same source as example 4; protein content = 90% w/w) and 10.9% lactose was mixed with 720 grams of skim milk. The final protein
15 concentration of this solution was 2.7%

 Drinking yogurt was prepared in a comparable way as described for (drinking) yogurt A.

 Despite the lower protein concentration in drinking yogurt B, the product obtained had a higher viscosity than the
20 reference drinking yogurt A. A test panel evaluation resulted in a preference for the drinking yogurt B, based on a more pleasant mouth feel.

EXAMPLE 10

25 Use of the protein additive of the invention as a foaming agent in meringue

 The foaming capacity of the composition of the invention was tested in the preparation of meringue. Compositions were prepared according to the following table.

28

Composition (%)		
	Control	Invention
Castor sugar	98.2	98.2
Bipro™	1.8	
5 Bipro™ fibrils		1.8
Total	100	100

The Bipro™ protein is mixed with the sugar. Then 300 g thereof is added to a grease free mixing bowl (Hobart N
10 50). Subsequently, 150 g cold water is added and the composition thus obtained is mixed for 1 min (speed 1) and whipped for 6 min (speed 3).

After 6 min whipping, the amount of foam of the control composition is essentially equal to the composition of
15 the invention (**Figure 2A**). The composition of the invention leads to a foam that is more stiff than the control.

Subsequently the two variants of the foam were made into a meringue by adding 130 g sugar for each 200 g composition. The foam thus obtained is poured in small
20 quantities on grease free paper and dried in the oven for 30 minutes at 125°C. **Figure 2B** shows that the addition of a protein additive of the invention leads to a better formed meringue than when untreated Bipro™ is used.

The control meringue has an overrun of 98 % and a
25 penetration of 15 mm with the light-weight measuring probe (43 g). The meringue of the invention is more firm and has an overrun of 80 % and 10 mm penetration with the same measuring probe.

30 **EXAMPLE 11**

Use of the protein additive of the invention as a foaming agent in dessert applications

A solution of 3 % (w/v) of Bipro™ treated according

to the invention in water was whipped during 1 min. in a Hobart mixer, speed 3. The thus obtained foam has a volume of 1100% and a good stability.

To a solution of 3 % (w/v) of the protein of the invention extra calcium (0.13 %) was added as Ca-lactate and treated as above. The stability of the foam is the same as without the addition of calcium.

In a third experiment 10 % sugar is added to the calcium containing solution of the second experiment. The mixture thus obtained is whipped in the same way resulting in an overrun of 900%. The foam is more stable than without the sugar.

The same series of experiments was performed with Bipro™ that was not treated according to the invention. In order to obtain a reasonable amount of foam the solution had to be whipped for 5 min. in the Hobart in speed 3 to achieve an overrun of 700%.

It thus follows that the treatment of the invention leads to a higher foaming ability.

In order to test the use of the treated Bipro™ of the invention as a foamig additive in desserts, a solution of 3 % (w/v) of the protein of the invention and extra calcium (0.13 %) was mixed with 10 % sugar and 5 % instant starch (Cerestar 12170) and whipped for 3 minutes. Already after 1 minute a foam was obtained but after 3 minutes the foam was firm and short with an overrun of 400 %. Addition of 1% citric acid leads to an even better foam formation of about 600 %.

The foaming capacity as compared to untreated Bipro™ is spectacular.

EXAMPLE 12Cappuccino foamer

Recipe:

	A: DP 387	5 g	B: DP 387	5 g
5	Powdered sugar	3 g	Powdered sugar	3 g
	Bipro™	0.5 g	Protein of the invention	0.5 g

Cappuccino was made by mixing a cappuccino foamer (DP 387 from DMV International, the Netherlands), with sugar and the
10 reference protein Bipro™ (ex. A), or the product (spray dried) of the invention (ex. B.). Subsequently 100 ml of boiling water was poured on the powder mix, and the cappuccino foam was assessed after 5 minutes.

15		Foam height	Foam appearance, taste
	A:	7 mm	good foam, fine structure
	B:	10 mm	foam with firmer body as in A; more stable foam compared to A, milky, frothy.

20

The protein according to the invention clearly improves the foaming properties of a cappuccino foamer (**Figure 3**).

CLAIMS

1. Method for improving the functional properties
5 of globular proteins, comprising the steps of:

a) providing a solution of one or more globular
proteins, in which solution the protein is at least partially
aggregated in fibrils; and

b) performing one or more of the following steps in
10 random order:

i) adjusting the pH of the solution to about
neutral;

ii) increasing the salt concentration in the
solution;

15 iii) concentrating the solution;

iv) changing the solvent quality of the
solution.

2. Method as claimed in claim 1, wherein the
fibril-containing solution of the one or more globular
20 proteins is provided by heating a solution of the one or more
proteins above room temperature, preferably at a temperature
between 50 and 100°C, at a pH between 0.5 and 4, preferably
between 0.5 and 3.

3. Method as claimed in claim 2, wherein the
25 solution is heated during a period of at least 10 minutes,
preferably at least 1 hour, more preferably at least 6 hours,
even more preferably at least 8 hours.

4. Method as claimed in any one of the claims 2 and
3, wherein the solution is cooled before performing one or
30 more of steps i) to iv).

5. Method as claimed in claim 4, wherein the
solution is cooled to a temperature between denaturation

temperature and 20°C, preferably between denaturation temperature and 5°C.

6. Method as claimed in any one of the claims 2-5, wherein the heating is performed at a pH below 2.8, preferably below 2.5, more preferably below 2.2.

7. Method as claimed in claim 1, wherein the fibril-containing solution of the one or more globular proteins is provided by adding a denaturing agent to the solution.

8. Method as claimed in claim 7, wherein the denaturing agent is a hydrotropic or chaotropic agent.

9. Method as claimed in claim 7, wherein the denaturing agent is selected from the group consisting of ureum, guanidinium chloride, alcohols, such as methanol, ethanol, propanol, butanol, trifluorethanol.

10. Method as claimed in any one of the claims 3-5, wherein the solution has a pH of 0.5-14.

11. Method as claimed in any one of the claims 2-10, wherein the globular protein is a protein that is substantially non-denatured and is capable of being thermally denatured at a temperature at or above the denaturation temperature of the protein or capable of being chemically denatured.

12. Method as claimed in any one of the claims 2-11, further comprising the step of adding already formed fibrils to the solution prior to production of the fibril-containing solution.

13. Method as claimed in claim 12, wherein the already formed fibrils are obtainable by the method as claimed in any one of the claims 2-11.

14. Method as claimed in claim 12 or 13, wherein the amount of already formed fibrils based on the total amount of protein is more than 0 and less than 90%, preferably

between 10 and 80%, more preferably between 20 and 70%, even more preferably between 30 and 60%.

15 15. Method as claimed in any one of the claims 1-14, wherein the pH is increased to a value between 3.9 and 9, preferably to about neutral pH.

16. Method as claimed in any one of the claims 1-14, wherein the salt concentration is increased to a maximum of 0.2M, preferably to 0.1M.

10 17. Method as claimed in claim 16, wherein the salt used for increasing the salt concentration is the salt of a divalent ion, preferably calcium.

18. Method as claimed in any one of the claims 1-17, wherein step i) is performed prior to step ii).

15 19. Method as claimed in any one of the claims 1-18, wherein the solvent quality of the solution is changed by removing the denaturing agent.

20. Method as claimed in any one of the claims 1-19, further comprising the step of drying the solution to obtain a dry product.

20 21. Method as claimed in claim 20, wherein the drying comprises spray drying.

22. Method as claimed in any one of claims 20-21, wherein the dry product is a powder.

25 23. Method as claimed in claim 1-22, wherein the globular protein is selected from the group consisting of whey proteins, egg albumins, blood globulins, soy proteins, wheat proteins, in particular prolamines, potato proteins, pea proteins.

30 24. Method as claimed in claim 23, wherein the globular protein is a whey protein isolate, a whey protein concentrate, and preferably a whey protein concentrate enriched in β -lactoglobulin.

25. Method as claimed in claim 24, wherein the globular protein is the whey protein isolate Bipro™.

26. Method as claimed in any one of the claims 24 and 25, wherein the globular protein is β -lactoglobulin.

5 27. Protein additive based on a system of one or more proteins that are at least partially aggregated in fibrils, characterized in that the protein additive has improved functional properties as compared to a similar protein additive based on a system of the same one or more
10 proteins in the same concentration in which the proteins are not aggregated in fibrils.

 28. Protein additive as claimed in claim 27, wherein the functional properties are one or more of the following: foaming properties, thickening properties, gelling
15 properties and emulsifying properties.

 29. Protein additive obtainable by the method as claimed in any one of the claims 1-26.

 30. Protein additive as claimed in claim 27 or 28 obtainable by the method as claimed in any one of the claims
20 1-26.

 31. Protein additive as claimed in claim 27 or 28 in dry form obtainable by the method as claimed in any one of the claims 20-26.

 32. Protein additive as claimed in any one of the
25 claims 27-31 for use as a stabilizer of foams, dispersions and emulsions.

 33. Protein additive as claimed in any one of the claims 27-31 for use in dairy products.

 34. Protein additive as claimed in any one of the
30 claims 27-31 for use in meat products.

 35. Protein additive as claimed in any one of the claims 27-31 for use in paints.

36. Protein additive as claimed in any one of the claims 27-31 for use in toothpastes, cosmetics, deodorants.

37. Dairy product comprising the protein additive as claimed in any one of the claims 27-31.

5 38. Meat product comprising the protein additive as claimed in any one of the claims 27-31.

39. Paint comprising the protein additive as claimed in any one of the claims 27-31.

10 40. Toothpaste comprising the protein additive as claimed in any one of the claims 27-31.

41. Cosmetic comprising the protein additive as claimed in any one of the claims 27-31.

42. Deodorant comprising the protein additive as claimed in any one of the claims 27-31.

15 43. Protein composition comprising one or more particles having texturizing properties, wherein the protein molecules are aggregated into fibrils.

20 44. Protein composition as claimed in claim 43, wherein the texturizing properties comprise the ability to promote or modify the viscosity or gelling ability of a product containing the composition.

25 45. Protein composition as claimed in any one of the claims 43 and 44, wherein the fibrils have an aspect ratio, which is defined as the ratio between length and width or length and height or length and diameter, of 5 or higher.

46. Protein composition as claimed in any one of the claims 43-45, wherein the length of the fibrils is preferably equal to or above 100Å and equal to or below 1 mm, preferably below 100 µm.

Fig. 1A





Fig. 1B







Fig. 2



invention



reference



A

B

Fig. 3




Fig. 4

Bipro Bipro fibrils







Fig. 5




t=60 min



t=30 min




t=0 min

Fig. 6**t= 15 min****t= 30 min****t= 60 min**

Left cylinder: control (untreated Bipropionolone)
Right cylinder: product of the invention

Fig. 7



INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/13678

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A23J3/04 A23J3/06 A23J3/08 A23J3/14 A23J3/16
A23J3/18 A23L1/0562 A23C9/13 A23C9/154 A23L1/314
C09D189/00 A61L9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23J A23L A23C C09D A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DD 142 144 A (KUMMER SIEGFRIED; LCHAGWAA GURRAGTSCHAGIJN; RAEUBER HANS JOERG) 11 June 1980 (1980-06-11)	27-31, 43, 44
Y	* page 1, paragraph 1; page 2, paragraphs 1 and 3; example; claim *	40, 42
X	WO 98/31240 A (NESTLE SA ; KING SOLIS LUIS ROBERTO (EC); MOFFITT KENNETH RICHARD () 23 July 1998 (1998-07-23) * page 1, lines 3-5; page 2, lines 1-16; page 4, lines 6-15, example 1; claims 1-4, 6, 8, 11, 16 and 19 * -/--	27-31, 37, 38, 43, 44

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

5 May 2004

Date of mailing of the international search report

02/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Georgopoulos, N

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/13678

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEE S-P ET AL: "REDUCING WHEY SYNERESIS IN YOGURT BY THE ADDITION OF A THERMOLABILEVARIANT OF -LACTOGLOBULIN" BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, JAPAN SOC. FOR BIOSCIENCE, BIOTECHNOLOGY AND AGROCHEM. TOKYO, JP, vol. 58, no. 2, 1 February 1994 (1994-02-01), pages 309-313, XP000435775 ISSN: 0916-8451 * page 311, column 2, paragraph 3 - page 312, column 2, paragraph 2 *	43,44
Y	EP 0 604 684 A (CAMPINA MELKUNIE BV) 6 July 1994 (1994-07-06) * claims 1, 3, 10-13 *	1-26
Y	WO 93/00832 A (COMMW SCIENT IND RES ORG) 21 January 1993 (1993-01-21) * page 4, lines 1-20; claims 1, 6 and 12-14 *	1-26
X	US 5 480 973 A (CANT JONATHAN R ET AL) 2 January 1996 (1996-01-02) * column 1, lines 40-59; column 3, lines 4-13 and 45-67; examples 1-3; claims 1, 3, 9, 12 and 16-22 *	1,3,4, 23,24, 27-32, 43,44
X	EP 1 129 626 A (PROTEIN TECH INT) 5 September 2001 (2001-09-05)	27-32, 34,38, 43,44
Y	* page 3, lines 34-38; page 8, lines 49-58; page 9, lines 8-19 and 33-38; examples 1, 2, 6 and 7; claims 1, 18, 20, 21, 25, 33 and 34 *	1-26
X	US 5 437 885 A (DOTY STEVEN C ET AL) 1 August 1995 (1995-08-01)	27-32, 34,38, 43,44
Y	* column 2, lines 27-31; column 5, line 50 - column 6, line 18; column 7, line 53 - column 8, line 3; examples 1-3; claims 1, 2 and 5-12 *	1-26,40, 42
Y	WO 02/49442 A (CAMPBELL LYDIA JOHANNA ;UNIV HERIOT WATT (GB)) 27 June 2002 (2002-06-27) * page 2, line 25 - page 3, line 21; page 4, lines 20-26; page 6, line 31 - page 7, line 9; claims 1 and 3 *	1-26
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/13678

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/067689 A (AGRONOMIQUE INST NAT RECH ;DOUBLIER JEAN-LOUIS (FR); GARNIER CATHE) 6 September 2002 (2002-09-06)	1,3,4, 11, 20-24, 26-37, 39,41, 43,44
Y	* page 3, lines 15-20; page 4, line 29 - page 5, line 10 ;page 6, lines 30-37; example 3; claims 1, 4, 5, 18 and 20-26 *	1-26,40, 42
X	US 5 455 331 A (PEARCE ROBERT J) 3 October 1995 (1995-10-03)	27,28, 43,44
Y	* column 2, line 66 - column 4, line 19; claims 1, 8 and 16-20 *	1-26

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/13678

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DD 142144	A	11-06-1980	DD 142144 A1	11-06-1980
WO 9831240	A	23-07-1998	AU 5763198 A	07-08-1998
			BR 9714525 A	02-05-2000
			CA 2273980 A1	23-07-1998
			WO 9831240 A1	23-07-1998
			EP 0957691 A1	24-11-1999
			IN 184149 A1	17-06-2000
			JP 2001507939 T	19-06-2001
			ZA 9800271 A	13-07-1999
EP 0604684	A	06-07-1994	EP 0604684 A1	06-07-1994
			AT 154200 T	15-06-1997
			AU 664934 B2	07-12-1995
			AU 5267493 A	07-07-1994
			CA 2111668 A1	24-06-1994
			DE 69220374 D1	17-07-1997
			DK 604684 T3	26-01-1998
			JP 7123927 A	16-05-1995
			NZ 250400 A	27-04-1995
			US 5420249 A	30-05-1995
WO 9300832	A	21-01-1993	AU 666125 B2	01-02-1996
			WO 9300832 A1	21-01-1993
			CA 2112660 A1	21-01-1993
			EP 0593613 A1	27-04-1994
			IE 922194 A1	13-01-1993
			JP 6508751 T	06-10-1994
			NZ 243449 A	22-12-1994
US 5480973	A	02-01-1996	AT 143769 T	15-10-1996
			AU 657754 B2	23-03-1995
			AU 1648292 A	17-11-1992
			CA 2104863 A1	23-10-1992
			DE 69214445 D1	14-11-1996
			DE 69214445 T2	20-02-1997
			EP 0581814 A1	09-02-1994
			WO 9218018 A1	29-10-1992
			JP 3415146 B2	09-06-2003
			JP 6506589 T	28-07-1994
EP 1129626	A	05-09-2001	US 6355295 B1	12-03-2002
			AU 771079 B2	11-03-2004
			AU 2477701 A	30-08-2001
			AU 2477801 A	30-08-2001
			AU 755396 B2	12-12-2002
			AU 6967100 A	30-08-2001
			BR 0004240 A	02-10-2001
			BR 0102199 A	02-01-2002
			BR 0102288 A	18-12-2001
			CA 2310296 A1	29-08-2001
			CN 1310957 A	05-09-2001
			CN 1318315 A	24-10-2001
			CN 1323547 A	28-11-2001
			DE 1129626 T1	21-02-2002
			DE 1135993 T1	18-04-2002
			DE 1129629 T1	21-02-2002
			EP 1129626 A2	05-09-2001

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/13678

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1129626	A	EP 1135993 A2	26-09-2001
		EP 1129629 A2	05-09-2001
		ES 2165827 T1	01-04-2002
		ES 2165340 T1	16-03-2002
		ES 2165341 T1	16-03-2002
		GR 2001300063 T1	30-11-2001
		GR 2001300064 T1	30-11-2001
		HU 0005045 A2	28-02-2002
		HU 0100922 A2	28-12-2001
		HU 0100923 A2	28-12-2001
		JP 2001346544 A	18-12-2001
		NZ 509563 A	26-11-2002
		NZ 510199 A	25-10-2002
		NZ 510203 A	25-10-2002
		NZ 520357 A	28-02-2003
		NZ 520358 A	28-02-2003
		NZ 520359 A	28-02-2003
		NZ 520360 A	28-02-2003
		PL 345876 A1	10-09-2001
		PL 346197 A1	10-09-2001
		PL 346201 A1	10-09-2001
		RU 2218815 C2	20-12-2003
		TR 200103071 T3	21-01-2002
		ZA 200100536 A	18-07-2001
		ZA 200101638 A	30-08-2001
		ZA 200101640 A	30-08-2001
US 5437885	A	01-08-1995	NONE
WO 0249442	A	27-06-2002	AU 2228302 A
			EP 1351578 A1
			WO 0249442 A1
			GB 2385769 A
			US 2004047974 A1
			ZA 200305224 A
WO 02067689	A	06-09-2002	FR 2821244 A1
			WO 02067689 A1
US 5455331	A	03-10-1995	AT 96618 T
			DE 3885459 T2
			AU 616411 B2
			AU 1723888 A
			WO 8808673 A1
			CA 1335765 C
			DE 3885459 D1
			EP 0368864 A1
			JP 2503425 T
			JP 2818176 B2
			NZ 224615 A

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.